Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 23Terminated 5Withdrawn 2Suspended 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Extranodal NK-T-Cell 1Hodgkin Disease 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × romidepsin × Clear all
NCT04639843 2022-11-04

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT04233697 2020-08-13

Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

Columbia University

Phase 1 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡